# Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-ii-randomized-trial-comparing-sequential-first-line-everolimus-and-second/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert J. Motzer,Carlos H. Barrios,Tae Min Kim,S. Falcon,Thomas M. Cosgriff,W G Harker,Vichien Srimuninnimit,Ken Pittman,Roberto Sabbatini,Sun Young Rha,Thomas W. Flaig,Ray D. Page,Sevil Bavbek,J. Thaddeus Beck,Poulam M. Patel,F.Y. Cheung,Sunil Kumar Yadav,Edward Schiff,Xufang Wang,Julie Niolat,Dalila Sellami,Oezlem Anak,Jennifer J. Knox |
| Citations | 433 |
| DOI | 10.1200/jco.2013.54.6911 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2013.54.6911?role=tab |
| OpenAlex ID | https://openalex.org/W2037716205 |
| PMID | 25049330 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Tae Min Kim](https://scholariq.org/researchers/tae-min-kim/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Connective Tissue Growth Factor Research](https://scholariq.org/topics/connective-tissue-growth-factor-research/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.